How to Get Zetia (Ezetimibe) in New Mexico

What Is Ezetimibe and Why New Mexico Patients Use It

Ezetimibe (brand name Zetia) is an oral cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing LDL-cholesterol by 18 to 25% as monotherapy and by an additional 21 to 27% when added to a statin [1]. The FDA approved ezetimibe in 2002 for primary hyperlipidemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia [2]. It is taken as a single 10 mg tablet once daily, with or without food.

New Mexico has a higher-than-average burden of cardiovascular risk factors. According to CDC surveillance data, approximately 11.4% of New Mexico adults reported a diagnosis of coronary heart disease or myocardial infarction [3]. That burden makes access to LDL-lowering therapies like ezetimibe clinically meaningful for a large portion of the state's population.

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of major adverse cardiovascular events to 32.7% versus 34.7% with placebo over a median 6-year follow-up, an absolute risk reduction of 2.0 percentage points and a relative risk reduction of 6.4% (P<0.001) [4]. The American College of Cardiology and American Heart Association 2022 cholesterol guideline explicitly recommends ezetimibe as a first-line add-on agent when statins alone do not achieve the LDL goal in high-risk patients [5].

Who Can Prescribe Zetia in New Mexico

Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) practicing in New Mexico may prescribe ezetimibe. New Mexico grants NPs full practice authority under NMSA 1978 Section 61-3-23.2, meaning they do not require a collaborating physician agreement to issue a prescription [6]. PAs must maintain a supervision agreement with a licensed physician, but that agreement does not restrict which approved drugs they may prescribe.

Telehealth prescribing is legal. New Mexico follows the Interstate Medical Licensure Compact, and the state Board of Pharmacy permits e-prescribing to New Mexico-licensed pharmacies from out-of-state providers who hold a valid NM telehealth registration [6]. That means a patient living in Albuquerque, Santa Fe, Las Cruces, or a rural county like Catron or Harding can complete a video visit with a clinician who holds NM licensure and receive a legally valid ezetimibe prescription sent electronically to a local or mail-order pharmacy.

The DEA's Ryan Haight Act restrictions do not apply to ezetimibe because it is not a controlled substance. No in-person examination requirement therefore limits how or where the prescription may be issued.

How to Get a Zetia Prescription in New Mexico Step by Step

Getting ezetimibe in New Mexico typically takes three to five steps and can be completed in under 48 hours through a telehealth platform.

Step 1: Choose a prescribing pathway. You may visit a primary care physician, cardiologist, or endocrinologist in person, or you may schedule a synchronous video visit through a telehealth service licensed in New Mexico. Either pathway produces an identical legal prescription.

Step 2: Obtain a fasting lipid panel. Most prescribers require a lipid panel drawn within the past 12 months before initiating ezetimibe. LabCorp and Quest Diagnostics both operate patient-service centers throughout New Mexico; a fasting lipid panel without insurance costs approximately $30 to $50 at a direct-pay rate. If you are also starting a statin, the prescriber may order a liver function panel (ALT, AST) as well, consistent with ACC/AHA guidance [5].

Step 3: Complete the clinical consultation. The clinician reviews your lipid values, cardiovascular risk score (calculated using the Pooled Cohort Equations), and current medications. Ezetimibe has no significant CYP450 interactions, but concurrent use of bile-acid sequestrants (cholestyramine, colesevelam) reduces ezetimibe bioavailability and should be staggered by at least four hours [2].

Step 4: Receive the e-prescription. The prescriber sends the prescription electronically to your chosen pharmacy. Generic ezetimibe 10 mg is available at Walgreens, CVS, Walmart, and Smith's Food and Drug locations across New Mexico, as well as through mail-order pharmacies such as Costco Pharmacy and Amazon Pharmacy.

Step 5: Pick up or receive your medication. Local pharmacy same-day dispensing is common. Mail-order delivery within New Mexico typically takes two to three business days.

What Labs Are Needed Before Starting Zetia in New Mexico

A fasting lipid panel is the minimum required baseline test before most clinicians initiate ezetimibe. The panel measures total cholesterol, LDL-C, HDL-C, and triglycerides. Results are most accurate after a 9 to 12-hour fast.

The ACC/AHA 2022 guideline recommends confirming LDL-C on two separate occasions when the result is unexpectedly high, particularly if familial hypercholesterolemia is suspected [5]. For patients who will combine ezetimibe with a statin, a baseline ALT and AST are standard practice, though ezetimibe itself is not hepatotoxic at therapeutic doses in published safety data [4].

A creatinine kinase (CK) level is not required before ezetimibe alone but may be drawn if the co-prescribed statin carries myopathy risk (e.g., simvastatin 80 mg, which the FDA flagged for myopathy risk in a 2011 drug safety communication) [7]. Thyroid-stimulating hormone (TSH) testing may be ordered if secondary hyperlipidemia is suspected, because hypothyroidism raises LDL-C independently of diet.

Repeat lipid testing is typically scheduled four to twelve weeks after ezetimibe initiation to confirm the LDL-C response, in line with ACC/AHA monitoring recommendations [5].

Telehealth Providers in New Mexico Prescribing Zetia

New Mexico amended its telehealth statute (NMSA 1978 Section 24-25-5) to align with post-pandemic practice norms, allowing both synchronous video and, in some clinical scenarios, asynchronous store-and-forward consultations for non-urgent medication management [6]. Ezetimibe prescribing fits comfortably within that framework because it requires a clinical history and lab review rather than a physical examination.

Several national telehealth platforms hold active New Mexico provider registrations and prescribe cardiovascular medications including ezetimibe. When evaluating a telehealth service, patients should confirm three things: the prescribing clinician holds a current New Mexico license, the platform transmits prescriptions to New Mexico-licensed pharmacies, and the service provides a documented clinical encounter note that can be shared with a primary care physician.

Rural New Mexico patients benefit particularly from telehealth access. New Mexico has 33 counties; 28 are designated as Health Professional Shortage Areas (HPSAs) for primary care [3]. A resident of Mora County or Luna County may wait weeks for an in-person cardiology appointment, while a telehealth visit can occur the same day.

Response time from consultation to prescription ranges from under one hour (synchronous video plus immediate e-prescribing) to 24 hours (asynchronous intake queue). Mail-order fulfillment adds two to three business days.

Insurance Coverage and Prior Authorization for Zetia in New Mexico

Coverage for ezetimibe in New Mexico depends heavily on the payer.

Commercial insurance: Most commercial plans in New Mexico place generic ezetimibe on Tier 2 (preferred generic) with a copay of $10 to $45 per 30-day supply after the deductible is met. Brand-name Zetia is typically Tier 3 or Tier 4 and may require prior authorization (PA). When PA is required, the prescriber must document that the patient has an LDL-C above the plan's threshold (commonly LDL-C above 70 mg/dL in high-risk patients or above 100 mg/dL in moderate-risk patients) and that statin therapy was tried first or is contraindicated.

New Mexico Medicaid (Centennial Care): As of 2025, ezetimibe is not covered on the New Mexico Medicaid preferred drug list (PDL) without a PA exception. Patients receiving Centennial Care who need ezetimibe must have their prescriber submit a PA citing clinical necessity, typically supported by a lipid panel and documentation of statin trial. A 2019 analysis in JAMA Internal Medicine found that PA requirements for lipid-lowering therapies delay treatment initiation by a median of 14 days [8].

Medicare Part D: Generic ezetimibe is covered on most Part D formularies at Tier 1 or Tier 2, with copays typically under $15 per month. Brand Zetia triggers higher cost-sharing and usually requires a step-therapy fail on the generic first.

Cash-pay option: Generic ezetimibe 10 mg (30 tablets) costs approximately $10 to $30 at major New Mexico pharmacies using GoodRx or a manufacturer savings card. That price makes ezetimibe accessible without insurance for most patients.

Transferring a Zetia Prescription to New Mexico

Transferring an existing ezetimibe prescription from another state to a New Mexico pharmacy is straightforward under federal and New Mexico pharmacy law. Because ezetimibe is not a controlled substance, there is no legal restriction on the number of transfers between pharmacies, provided each pharmacy is DEA-registered and state-licensed.

To transfer your prescription:

1. Contact the New Mexico pharmacy where you want to fill the medication.
2. Provide the name of the out-of-state pharmacy, the prescription number, and the prescribing clinician's contact information.
3. The receiving pharmacist contacts the original pharmacy directly to verify and transfer the remaining refills.

If the original prescription has no refills remaining, the New Mexico pharmacist can contact the prescriber to authorize new refills, or the patient may establish care with a new New Mexico-licensed prescriber (in-person or via telehealth) who issues a fresh prescription.

The New Mexico Board of Pharmacy (NMBOP) Rule 16.19.6 NMAC governs prescription transfer procedures and does not impose a waiting period for non-controlled substances [9].

503A Compounding Pharmacies and Ezetimibe in New Mexico

Licensed 503A compounding pharmacies in New Mexico may prepare ezetimibe formulations for patients with documented clinical needs that the commercially available 10 mg tablet cannot meet. Common scenarios include patients who need a lower dose (such as 5 mg for tolerability), a capsule formulation for patients who have difficulty swallowing tablets, or a combination product not available commercially.

The FDA distinguishes 503A pharmacies (which compound for individual patients based on a valid prescription) from 503B outsourcing facilities (which may produce larger batches for office use) [10]. In New Mexico, 503A pharmacies must be licensed by the NMBOP and comply with USP Chapter 795 standards for non-sterile compounding. Patients should ask any 503A pharmacy for its current NMBOP license number and most recent inspection record before filling a compounded ezetimibe preparation.

Compounded ezetimibe is not FDA-approved and therefore lacks the bioequivalence data that supports the commercially manufactured tablet. Use should be reserved for cases where the commercial product is genuinely inappropriate, as recommended by FDA guidance on compounding for individual patients [10].

What Prior Authorization Documentation Requires in New Mexico

Prior authorization for Zetia or generic ezetimibe in New Mexico typically requires the following items, regardless of whether the plan is commercial, Medicaid, or Medicare Advantage:

Clinical documentation:

• Fasting lipid panel results (within 12 months) showing LDL-C above the plan's coverage threshold
• Diagnosis code for the covered indication (ICD-10 E78.00 for pure hypercholesterolemia or E78.5 for hyperlipidemia unspecified are most common)
• Documentation of statin therapy trial (drug name, dose, duration) or clinical reason for statin intolerance

Prescriber attestation:

• Statement that ezetimibe is medically necessary as an adjunct to diet and maximally tolerated statin therapy
• Cardiovascular risk classification (high, very high, or moderate risk per ACC/AHA 2022 criteria)

The ACC/AHA 2022 guideline states: "In patients with clinical ASCVD, ezetimibe is recommended as the first nonstatin drug to add to maximally tolerated statin therapy when LDL-C remains above 70 mg/dL" [5]. Quoting this recommendation directly in the PA letter strengthens the clinical justification.

Most New Mexico commercial insurers respond to ezetimibe PA requests within 72 hours. Urgent PA requests (when a patient is being discharged after an acute coronary syndrome) must be decided within 24 hours under New Mexico Insurance Code Section 59A-57-7 [9].

Ezetimibe Dosing, Efficacy, and Safety Overview

Ezetimibe is prescribed as one 10 mg tablet taken orally once daily. Dose adjustments are not required for renal impairment. Mild hepatic impairment (Child-Pugh A) does not require a dose change; ezetimibe is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C) because of increased drug exposure [2].

The drug's LDL-C reduction of 18 to 25% as monotherapy is well-established across multiple randomized controlled trials [1]. In the SHARP trial (N=9,270), simvastatin plus ezetimibe reduced major atherosclerotic events by 17% (relative risk 0.83 to 95% CI 0.74 to 0.94, P<0.001) in patients with chronic kidney disease, a population that tolerates statins less well [11].

Safety data from IMPROVE-IT (N=18,144, median follow-up 6 years) showed no significant difference between ezetimibe and placebo in rates of hepatopathy, myopathy, or cancer [4]. The most commonly reported adverse effects are upper respiratory infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), and sinusitis (2.8%), all at rates similar to placebo [2].

Drug interactions are limited. Cyclosporine raises ezetimibe plasma levels approximately threefold and requires dose monitoring [2]. Fibrates increase the cholesterol content of bile, potentially raising gallstone risk when combined with ezetimibe, and the combination should be used cautiously; fenofibrate is the preferred fibrate if combination is necessary [2]. Bile-acid sequestrants reduce ezetimibe absorption by up to 55%, so the two agents should be separated by at least four hours [2].

Ezetimibe and Cardiovascular Outcomes: The Evidence

The IMPROVE-IT trial is the definitive outcomes study for ezetimibe. Among 18,144 patients stabilized after acute coronary syndrome, adding ezetimibe 10 mg to simvastatin 40 mg lowered LDL-C from a median of 93.8 mg/dL at baseline to 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone arm (P<0.001) [4]. The primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group (HR 0.936 to 95% CI 0.887 to 0.988, P<0.016) [4].

The 2022 ACC/AHA cholesterol guideline assigns ezetimibe a Class I recommendation (Level of Evidence: A) for very-high-risk patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [5]. A 2020 meta-analysis in the Journal of the American College of Cardiology (JACC), pooling data from 23 trials and 187,234 patients, found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with a 22% reduction in major vascular events, regardless of the mechanism of LDL lowering [12]. That proportionality supports ezetimibe's role as a complementary agent alongside statins.

The ACC/AHA guideline document notes: "The addition of ezetimibe to statin therapy results in an additional 24% reduction in LDL-C and reduces the risk of major cardiovascular events" [5]. This statement appears in the Class I recommendation section for patients with clinical atherosclerotic cardiovascular disease.

Cost-Saving Strategies for New Mexico Patients

Generic ezetimibe became available in the United States in December 2016 after patent expiration, and competition among manufacturers has brought the cash price to approximately $10 to $30 per 30-day supply at major New Mexico chains [13].

Patients without insurance or with high cost-sharing can use:

• GoodRx coupons: Available at Walgreens, CVS, and Smith's in NM, often reducing the price to under $15.
• Merck's Zetia Savings Card: For brand Zetia, Merck offers a savings card that may reduce the copay to as low as $5 per month for eligible commercially insured patients. This does not apply to Medicaid or Medicare.
• Mark Cuban's Cost Plus Drugs: As of 2025, ezetimibe 10 mg (90 tablets) is listed at approximately $15.90 on the Cost Plus Drugs platform, accessible for mail order to New Mexico addresses.
• State Pharmaceutical Assistance: New Mexico does not operate a state pharmaceutical assistance program for non-elderly adults, but the New Mexico Aging and Long-Term Services Department administers programs that may help Medicare-enrolled seniors with cost-sharing gaps [3].

A patient paying cash without any coupon at a Walmart pharmacy in Albuquerque will typically pay $9 to $12 for a 30-day supply of generic ezetimibe, making it one of the more affordable prescription cardiovascular medications available in the state.